Acquisition of the RAPID drug discovery platform and rare disease pipeline through the acquisition of Jnana Therapeutics

An individual M&A transaction to acquire Jnana Therapeutics as a wholly owned subsidiary, together with its proprietary RAPID drug discovery platform, the phenylketonuria drug candidate JNT-517, and small-molecule pipelines for autoimmune and other diseases.